Pharmacokinetics and pharmacodynamics of newer oral cephalosporins. Implications for treatment of community-acquired lower respiratory tract infections

Clinical Drug Investigation

Volumn 16, Issue 4, 1998, Pages 335-346

  Cazzola, M ^a   Matera, M G ^a   Donner, C F ^a  

^a IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE;

BACTERICIDAL ACTIVITY; BRONCHUS SECRETION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0031770509     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816040-00008     Document Type: Review

References (86)

1. Ball P, Tillotson G, Wilson R, Chemotherapy for chronic bronchitis. Controversies. Presse Med 1995; 24: 189-94
2. Ball P, Harris JM, Lowson D. et al. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-8
3. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146; 1067-83
4. Cazzola M. Problems and prospectives in the antibiotic treatment of lower respiratory tract infections. Pulm Pharmacol 1944; 7: 139-52
5. Cazzola M. Infektionen der tiefen Atemwege in der Algemeinpraxis. Infection 1987; 15 Suppl. 3: S113-9
6. Floreani AA, Buchalter SE: Sisson JH, et al. Chronic bronchitis. In: Pennington JE, editor. Respiratory infections: diagnosis and management. 3rd ed. New York: Raven Press, 1994: 149-92
7. Smith CB, Golden C, Klauber MR, et al. Interaction between viruses and chronic bronchitis. J Infect Dis 1976; 134: 552-61
8. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420
9. Staley H, McDade HB, Paes D. Is an objective assessment of antibiotic therapy in exacerbations of chronic bronchitis possible? J Antimicrob Chemother 1993; 31: 193-9
10. Taylor DC, Clancy RL, Cripps AW, et al. An alteration in the host-parasite relationship in subjects with chronic bronchitis prone to recurrent episodes of acute bronchitis. Immunol Cell Biol 1994; 72: 143-51
11. Cazzola M. Lower respiratory tract infections in general practice. RSM Int Congr Symp Series 1986; 109: 45-55
12. Geddes AM. Empiric therapy in lower respiratory tract infection - an ongoing challenge. J Chemother 1997; 9 Suppl. 3: 5-9
13. Jacobs MR. Respiratory tract infection: epidemiology and surveillance. J Chemother 1997; 9 Suppl. 3 10-7
14. Pozzi E, Oliva A. Oral cephalosporins: clinical results in lower respiratory tract infections. Antibiot Chemother 1995; 47: 123-44
15. Jones RN. In vitro antibacterial activity of oral cephalosporins. A selective and comparative review. Clin Drug Invest 1995; 9 Suppl. 3: 22-30
16. Cullmann W. Microbiology of oral cephalosporins. Antibiot Chemother 1995; 47: 72-109
17. Lode H, Fassbender M, Schaberg T, et al. Comparative pharmacokinetics of the new oral cephalosporins. Drugs 1994: 47 Suppl. 3: 10-9
18. Craig WA. Selecting the antibiotic. Hosp Pract 1993; 28 Suppl. 1: 16-20
19. Cazzola M, Matera MG. Interrelationship between pharmacokinetics and pharmacodynamics in choosing the appropriate antibiotic and the dosage regimen tor treating acute exacerbations of chronic bronchitis. Respir Med. In press
20. Cars O, Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharinacodynamics. Diagn Microbiol Infect Dis 1997; 27: 29-34
21. Odenholt-Tornqvist I, Lowdin E, Car O. Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro. Antimicrob Agents Chemother 1991; 35: 1834-9
22. Shentag JJ, Smith H, Swanson DJ, et al. Role of dual individualization with cefmenoxime. Am J Med 1984; 77 Suppl. 6A: 43-50
23. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 25: 89-96
24. Craig WA, Leggett J, Toutsuka K, et al. Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections. J Drug Dev 1988; 1 Suppl. 3: 7-15
25. Ciaig WA, Ebert S, Watanabe Y. Differences in time above MIC required for efficacy of beta-lactams in animal infection models [abstract 86]. Proceedings and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995; 135 Sept 17-20 San Francisco, Calif., USA
26. Andes D, Urban A, Craig WA. In vitro activity of amoxicillin and amoxicillin-clavulanate against penicillin-resistant pneumococci [abstract A82]. Proceedings and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995: 16 Sept 17-20 San Francisco, Calif., USA
27. Urban A, Andes D, Craig WA. In-vivo activity of cefpodoxime against penicillin-resistant pneumococci [abstract 2229]. Final Program and Abstracts of the 19th International Congress of Chemotherapy; 1995 Jul 16-21: Montreal: 381C
28. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 Suppl. 3: 38-44
29. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25: 213-7
30. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in acute otilis media Pediatr Infect Dis J 1996; 15 Suppl. 3: 255-9
31. Cazzola M, Noschese P, Vinciguerra A, et al. Le correlazioni esistenti fra farmacocinetica polmonare e farmacodinamica permetlono di ipotizzare l'utilizzo del cetlazidime alla dose di l g una sola volta al giorno nel trattamento delle riacutizzazioni batteriche della broncopneumopatia cronica ostruttiva con danno funzionale moderato. Min Med 1998; 89: 15-22
32. Stoeckel K, Hayton WL, Edwards DJ. Clinical pharmacokinetics of oral cephalosporins. Antibiot Chemother 1995; 47: 34-71
33. Baldwin DR. The penetration of novel intravenous cephalosporins into the lung. J Chemother 1996; 8 Suppl 2: 71-82
34. Nix DE, Goodwin SD, Peluquin CA, et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 1991; 35: 1953-9
35. Maesen FP, Beeuwkes H, Davies BI, et al. Bacampicillin in acute exacerbations of chronic bronchitis - a dose-range study. J Antimicrob Chemother 1976; 2: 279-85
36. Stewart SM, Fisher M, Young JE, et al. Amoxycillin levels in sputum, serum and saliva. Thorax 1974; 29: 110-4
37. Maesen FP, Geraedts WH, Davies BI. Cefaclor in the treatment of chronic bronchitis. J Antimicrob Chemother 1990; 26: 456-8
38. Cazzola M, Caputi M, Santangeto G, et al. A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease. J Chemother 1997; 9: 279-84
39. Bergogne-Bérézin E. Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 1981; 8: 171-4
40. Cazzola M, Matera MG, Cirella M, et al. Penetrazione del cefaclor nell'espettorato dopo somministrazione singola e multipla: confronto fra la preparazione a rilascio classico e una nuova formulazione a rilascio modificato. Giormale Italiano Ricerche Cliniche e Terapeutiche 1995; 16: 37-41
41. Bergogne-Bérézin E, Vallée E. Pharmacokinetics of antibiotics in respiratory tissues and fluid. In: Pennington JE, editor. Respiratory infections: diagnosis and management. 3rd ed. New York: Raven Press, 1994: 715-40
42. Cazzola M, Matera MG, Polverino M, et al. Pulmonary penetration of ceftazidime. J Chemother 1995; 7: 50-4
43. Cazzola M, Diamare F, Vinciguerra A, et al. La penetrazione polmonare degli antibiotici e il suo impatto clinico. Rass Pat App Respir 1996; 11: 134-47
44. Wise R, Baldwin DR, Honeybourne D. Penetration of antibiotics into the bronchial mucosa. Res Clin Forums 1990; 12 (4): 95-100
45. Baldwin DR, Andrews JM, Wise R, et al. Bronchoalveolar distribution of cefuroxime axetil and in vitro efficacy of observed concentrations against respiratory pathogens. J Antimicrob Chemother 1992; 30: 377-85
46. Marlin GE, Nicholls AJ, Funnell GR, et al. Penetration of cefaclor into bronchial mucosa. Thorax 1984; 39: 813-7
47. Bergogne-Bérézin E. New concepts in the pulmonary disposition of antibiotics. Pulm Pharmacol 1995; 8: 65-81
48. Bergogne-Berezin E. Cefpodoxime proxetil in upper respiratory tract infections. Drugs 1991; 42 Suppl. 3: 25-33
49. Muller-Serieys C, Bancal C, Dombret MC, et al. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. Antimicrob Agents Chemother 1992; 36: 2099-103
50. Baldwin DR, Wise R, Andrews JM, et al. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. J Antimicrob Chemother 1992; 30: 67-71
51. Baldwin DR, Andrews JM, Ashby JP, et al. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax 1990; 45: 401-2
52. Grellet J, Couraud L, Saux MC, et al. Diffusion pulmonaire du cefixime chez l'homme. Presse Méd 1989; 18: 1589-92
53. Blouin RA, Stoeckel K. Cefetamet pivoxil clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 172-88
54. Scaglione F, Cogo R, Raschi S, et al. Studio clinico e farmacocinetico di cefetarnet pivoxil in confronto con il cefixime nella bronchite cronica riacutizzata. Antibioticoterapia per la pratica 1995; 3: 92-7
55. Emmerson AM. The clinical significance of tissue concentrations. Res Clin Forums 1990; 12 (4): 117-21
56. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Anlimicrob Chemother 1993; 31 Suppl. D: 1-16
57. Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 1991; 35: 1953-9
58. Nye K, O'Neill P, Andrews JM, et al. Pharmacokinetics and tissue penetration of cefprozil. J Antimicrob Chemother 1990; 25: 831-5
59. Zimmerli W, Sansano S, Wittke B. Pharmacokinetics of cefetamet in plasma and skin blister fluid. Antimicrob Agents Chemother 1996; 40: 102-4
60. Wise R, Bennett SA, Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 1984; 13: 603-10
61. O'Neill P, Nye K, Douce G, et al. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetif in volunteers. Antimicrob Agents Chemother 1990; 34: 232-4
62. Barbhaiya RH, Shukla UA, Gleason CR, et al. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1990; 34: 1204-9
63. Wise R, Nye K, O'Neill P, et al. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990; 34: 1053-5
64. Richer M, Allard S, Manseau L, et al. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses. Antimicrob Agents Chemother 1995; 39: 1082-6
65. Neu HC. Ceftibuten: minimal inhibitory concentrations, postantibiotic effect, beta-lactamase stability - a rationale for dosing programs. Pediatr Infect Dis J 1993; 12: S49-54
66. Wise R. Comparative microbiological activity and pharmacokinetics of cefprozil. Eur J Clin Microbiol Infect Dis 1994; 13: 833-45
67. Schentag JJ. Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet 1989; 16 Suppl. 1: 25-31
68. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289-97
69. Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 1995; 28: 361-84
70. Kneer J. Pharmacokinetic properties of new oral cephalosporins. Méd Mal Infect 1992; 22: 556-64
71. Wise R, Gillet AP, Cadge B, et al. The influence of protein binding upon tissue fluid levels of six β-lactam compounds. J Infect Dis 1980; 142: 77-82
72. Stem GE, Schooley S, Walker RD, et al. Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae. Pharmacotherapy 1997; 17: 235-41
73. Stratum CW. Serum bactericidal test. Clin Microbiol Rev 1988; 1: 19-26
74. Lemmen SW, Hauer T, Anding K, et al. Serum bactericidal activity against Moraxella catarrhalis and Streptotococcus pneumoniae after administration of four oral cephalosporins in healthy volunteers. J Antimicrob Chemother 1995; 35: 233-5
75. Dan M, Poch F, Edelman A, et al. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers. J Antimicrob Chemother 1998; 41: 485-8
76. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore: The William & Wilkins Co., 1996: 296-329
77. Chin NX, Huang HB, Neu HC. Postantibiotic effect of ceftibuten on respiratory pathogens. Pediatr Infect Dis J 1993; 12: S45-48
78. Sieebor E et al. Abstracts of the International Conference of Infectious Diseases; 1990 Jul 15-19 Montreal
79. Odenholt I, Löwdin E, Cars O. Studies of the killing of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. Amimicrob Agents Chemother 1997; 41: 2522-6
80. Cars O, Odenholt-Tornqvist I. The postantibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 1993; 31 Suppl. D: 159-66
81. Spangler SK, Lin G, Jacobs MR, et al. Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1997; 41: 2173-6
82. Darveau RP, Cunningham MD. Influence of subinhibitory concentrations of cephalosporins on the serum sensitivity of Pseudomonas aeruginosa. J Infect Dis 1990; 162: 914-21
83. Tripoldi MF, Adinolfi LE, Utili R, et al. Influence of subinhibitory concentrations of loracarbef (LY 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity. J Antimicrob Chemother 1990; 26: 491-501
84. Labro MT, el Benna J, Jemni A. Modification des bacteries induites par le cefixime a concentrations subinhibitrices: consequences sur l'activite bactericide des polynucleaires neutrophiles humains. Pathol Biol (Paris) 1992; 40: 427-32
85. Tsang KW, Rutman A, Kanthukumar K, et al. Haemophilus influenzae infection of human respiratory mucosa in low concentrations of antibiotics. Am Rev Respir Dis 1993; 148: 201-7
86. Gengo FM, Mannion TW, Nightngale CH, et al. Integration of pharmacokinetics and pharmacadynamics of methicillin in curative treatment of experimental endocarditis. J Antimicrob Chemother 1984; 14: 619-31